Cheryl Hull, MD
Dermatology · Rogers, ARNPI 1124081849
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,854 of the $5,838 with a category attached, or 66.0%. 19 manufacturers reported payments, led by AbbVie at 39.3% of the total. Reporting peaked in 2023 at $1,475 and has fallen 54.1% since, to $677 in 2025.
Across 164 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Arcutis Biotherapeutics, Inc.$868
- Galderma Laboratories, L.p.$637
- Novartis$307
- Lilly USA, LLC$256
- Regeneron Healthcare Solutions, Inc.$233
- plus $1K from 13 others
Across 1,058 payments — averaging $2604.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$959K
- Eli Lilly$482K
- Incyte Corporation$459K
- Bausch Health US, LLC$233K
- AbbVie$188K
- Dr.reddy's Laboratories,inc.$119K
- plus $316K from 16 others
What the payments were for
- Consulting fees$82514%
- Speaking & faculty fees$1,14520%
- Food & beverage$3,85466%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $2,294 |
| Arcutis Biotherapeutics, Inc. | 3 | $868 |
| Galderma Laboratories, L.p. | 15 | $637 |
| Novartis | 15 | $307 |
| Lilly USA, LLC | 9 | $256 |
| Regeneron Healthcare Solutions, Inc. | 6 | $233 |
| Johnson & Johnson | 9 | $209 |
| Sanofi | 6 | $188 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $167 |
| Sun Pharmaceutical Industries Inc. | 6 | $139 |
| Sanofi-aventis U.S. LLC | 2 | $132 |
| Dermavant Sciences, Inc. | 1 | $110 |
| Amgen | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Bausch Health US, LLC | 1 | $45 |
| Sandoz | 2 | $38 |
| Organogenesis Inc. | 1 | $31 |
| Revance Therapeutics, Inc. | 1 | $25 |
| Strata Skin Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$235
- NEMLUVIO$134
- Tremfya$125
- SOOLANTRA$124
- EPIDUO FORTE$124
- ORACEA$124
- BOTOX COSMETIC$123
- EBGLYSS$121
- VTAMA$110
How this compares
$5,838 in reported general payments places this provider in the 70th percentile of 75 dermatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $293,875 |
| OtezlaApremilast | 32 | $163,731 |
| Dupixent PenDupilumab | 30 | $109,527 |
| Taltz AutoinjectorIxekizumab | 13 | $88,755 |
| Ketoconazole | 547 | $7,124 |
| Clobetasol Propionate | 104 | $4,558 |
| Tretinoin | 42 | $2,746 |
| Acitretin | 11 | $2,412 |
| Doxycycline Hyclate | 140 | $2,272 |
| ZenataneIsotretinoin | 13 | $2,263 |
| Metronidazole | 37 | $1,964 |
| Triamcinolone Acetonide | 241 | $1,888 |
| Fluorouracil | 27 | $1,783 |
| Clindamycin Phosphate | 64 | $1,780 |
| Tacrolimus | 20 | $1,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $98 | $163,73132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 75 dermatology providers in Arkansas.
Other dermatology in Rogers
- Ryan RichRogers$5K
- Michael GaroneRogers$5K
- Lauren McCaslinRogers$4K
- Sandra JohnsonFort Smith$543K
- Scott JacksonFayetteville$533K
- Mildred CliftonBentonville$92K
- Lance HenryFayetteville$39K
- Jennifer JacksPine Bluff$21K
- Zachary NahmiasJonesboro$15K
- Phillip StitesFort Smith$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.